AAPL343.91-3.82 (-1.10%) ▼|ABBV286.74+1.10 (+0.39%) ▲|ABT104.88+1.18 (+1.14%) ▲|ACN247.23-2.14 (-0.86%) ▼|ADBE258.62-5.20 (-1.97%) ▼|AMAT387.59+10.35 (+2.74%) ▲|AMD531.28+14.49 (+2.80%) ▲|AMGN444.63+5.37 (+1.22%) ▲|AMT188.28-0.69 (-0.37%) ▼|AMZN249.09+1.09 (+0.44%) ▲|AVGO329.17+7.49 (+2.33%) ▲|AXP315.05+1.83 (+0.58%) ▲|BA188.31-0.04 (-0.02%) ▼|BAC50.52-0.04 (-0.08%) ▼|BKNG153.14-2.69 (-1.73%) ▼|BLK1,127.66+9.41 (+0.84%) ▲|BMY61.61+0.13 (+0.21%) ▲|BNY147.18+2.54 (+1.76%) ▲|BRK-B548.56+6.37 (+1.17%) ▲|C121.04+0.42 (+0.35%) ▲|CAT692.13+6.76 (+0.99%) ▲|CL93.10-0.94 (-1.00%) ▼|CMCSA22.05-0.64 (-2.82%) ▼|COF202.35+1.01 (+0.50%) ▲|COP151.37+0.57 (+0.38%) ▲|COST1,005.16+1.84 (+0.18%) ▲|CRM247.61-0.96 (-0.39%) ▼|CSCO110.24+3.74 (+3.51%) ▲|CVS92.53-0.94 (-1.01%) ▼|CVX232.01-1.20 (-0.51%) ▼|DE641.25-4.90 (-0.76%) ▼|DHR232.97+2.47 (+1.07%) ▲|DIS110.40-2.12 (-1.88%) ▼|DUK124.44-0.54 (-0.43%) ▼|EMR161.70+0.11 (+0.07%) ▲|FDX300.58+1.86 (+0.62%) ▲|GD357.04+7.68 (+2.20%) ▲|GE288.43+2.79 (+0.98%) ▲|GEV855.12+40.12 (+4.92%) ▲|GILD158.69+2.65 (+1.70%) ▲|GM76.31+0.39 (+0.51%) ▲|GOOG314.19-3.09 (-0.97%) ▼|GOOGL316.80-3.41 (-1.06%) ▼|GS893.28+17.60 (+2.01%) ▲|HD319.38-0.45 (-0.14%) ▼|HON219.28-1.87 (-0.85%) ▼|IBM253.44-0.12 (-0.05%) ▼|INTC90.47+3.51 (+4.04%) ▲|INTU339.89-3.50 (-1.02%) ▼|ISRG451.63-0.66 (-0.15%) ▼|JNJ266.30+2.49 (+0.94%) ▲|JPM334.04+2.46 (+0.74%) ▲|KO92.70-0.01 (-0.01%) ▼|LIN507.56-1.27 (-0.25%) ▼|LLY1,279.14+5.68 (+0.45%) ▲|LMT635.20+31.02 (+5.13%) ▲|LOW198.22-0.46 (-0.23%) ▼|LRCX237.50+7.40 (+3.22%) ▲|MA613.50-10.10 (-1.62%) ▼|MCD250.83+2.37 (+0.95%) ▲|MDLZ62.97-0.83 (-1.30%) ▼|MDT94.79-0.62 (-0.65%) ▼|META630.56-12.06 (-1.88%) ▼|MMM172.79-0.67 (-0.39%) ▼|MO73.62-0.69 (-0.93%) ▼|MRK140.61-4.66 (-3.21%) ▼|MS183.49+4.00 (+2.23%) ▲|MSFT532.60+8.09 (+1.54%) ▲|MU903.70+26.15 (+2.98%) ▲|NEE82.04-0.06 (-0.07%) ▼|NFLX63.90-1.95 (-2.96%) ▼|NKE37.91+0.61 (+1.64%) ▲|NOW158.18-0.78 (-0.49%) ▼|NVDA216.00+5.04 (+2.39%) ▲|ORCL126.06-0.10 (-0.08%) ▼|PEP135.46-0.31 (-0.23%) ▼|PFE29.79-0.24 (-0.80%) ▼|PG159.92-1.10 (-0.68%) ▼|PLTR198.84+2.09 (+1.06%) ▲|PM201.87+2.40 (+1.20%) ▲|QCOM179.60+3.69 (+2.10%) ▲|RTX197.48+6.47 (+3.39%) ▲|SBUX102.69+1.89 (+1.88%) ▲|SCHW89.73-0.85 (-0.94%) ▼|SO92.57-0.32 (-0.34%) ▼|SPG212.69+1.06 (+0.50%) ▲|T20.85-0.08 (-0.38%) ▼|TMO684.89+11.07 (+1.64%) ▲|TMUS146.93+0.39 (+0.27%) ▲|TSLA391.62+19.40 (+5.21%) ▲|TXN298.12+13.43 (+4.72%) ▲|UBER66.13-0.57 (-0.85%) ▼|UNH410.70-7.39 (-1.77%) ▼|UNP296.97+4.10 (+1.40%) ▲|UPS100.32-0.74 (-0.73%) ▼|USB59.70+0.12 (+0.20%) ▲|V404.16-3.76 (-0.92%) ▼|VZ43.10-1.56 (-3.49%) ▼|WFC82.65+0.26 (+0.32%) ▲|WMT120.29+0.40 (+0.33%) ▲|XOM184.54+1.33 (+0.73%) ▲|AAPL343.91-3.82 (-1.10%) ▼|ABBV286.74+1.10 (+0.39%) ▲|ABT104.88+1.18 (+1.14%) ▲|ACN247.23-2.14 (-0.86%) ▼|ADBE258.62-5.20 (-1.97%) ▼|AMAT387.59+10.35 (+2.74%) ▲|AMD531.28+14.49 (+2.80%) ▲|AMGN444.63+5.37 (+1.22%) ▲|AMT188.28-0.69 (-0.37%) ▼|AMZN249.09+1.09 (+0.44%) ▲|AVGO329.17+7.49 (+2.33%) ▲|AXP315.05+1.83 (+0.58%) ▲|BA188.31-0.04 (-0.02%) ▼|BAC50.52-0.04 (-0.08%) ▼|BKNG153.14-2.69 (-1.73%) ▼|BLK1,127.66+9.41 (+0.84%) ▲|BMY61.61+0.13 (+0.21%) ▲|BNY147.18+2.54 (+1.76%) ▲|BRK-B548.56+6.37 (+1.17%) ▲|C121.04+0.42 (+0.35%) ▲|CAT692.13+6.76 (+0.99%) ▲|CL93.10-0.94 (-1.00%) ▼|CMCSA22.05-0.64 (-2.82%) ▼|COF202.35+1.01 (+0.50%) ▲|COP151.37+0.57 (+0.38%) ▲|COST1,005.16+1.84 (+0.18%) ▲|CRM247.61-0.96 (-0.39%) ▼|CSCO110.24+3.74 (+3.51%) ▲|CVS92.53-0.94 (-1.01%) ▼|CVX232.01-1.20 (-0.51%) ▼|DE641.25-4.90 (-0.76%) ▼|DHR232.97+2.47 (+1.07%) ▲|DIS110.40-2.12 (-1.88%) ▼|DUK124.44-0.54 (-0.43%) ▼|EMR161.70+0.11 (+0.07%) ▲|FDX300.58+1.86 (+0.62%) ▲|GD357.04+7.68 (+2.20%) ▲|GE288.43+2.79 (+0.98%) ▲|GEV855.12+40.12 (+4.92%) ▲|GILD158.69+2.65 (+1.70%) ▲|GM76.31+0.39 (+0.51%) ▲|GOOG314.19-3.09 (-0.97%) ▼|GOOGL316.80-3.41 (-1.06%) ▼|GS893.28+17.60 (+2.01%) ▲|HD319.38-0.45 (-0.14%) ▼|HON219.28-1.87 (-0.85%) ▼|IBM253.44-0.12 (-0.05%) ▼|INTC90.47+3.51 (+4.04%) ▲|INTU339.89-3.50 (-1.02%) ▼|ISRG451.63-0.66 (-0.15%) ▼|JNJ266.30+2.49 (+0.94%) ▲|JPM334.04+2.46 (+0.74%) ▲|KO92.70-0.01 (-0.01%) ▼|LIN507.56-1.27 (-0.25%) ▼|LLY1,279.14+5.68 (+0.45%) ▲|LMT635.20+31.02 (+5.13%) ▲|LOW198.22-0.46 (-0.23%) ▼|LRCX237.50+7.40 (+3.22%) ▲|MA613.50-10.10 (-1.62%) ▼|MCD250.83+2.37 (+0.95%) ▲|MDLZ62.97-0.83 (-1.30%) ▼|MDT94.79-0.62 (-0.65%) ▼|META630.56-12.06 (-1.88%) ▼|MMM172.79-0.67 (-0.39%) ▼|MO73.62-0.69 (-0.93%) ▼|MRK140.61-4.66 (-3.21%) ▼|MS183.49+4.00 (+2.23%) ▲|MSFT532.60+8.09 (+1.54%) ▲|MU903.70+26.15 (+2.98%) ▲|NEE82.04-0.06 (-0.07%) ▼|NFLX63.90-1.95 (-2.96%) ▼|NKE37.91+0.61 (+1.64%) ▲|NOW158.18-0.78 (-0.49%) ▼|NVDA216.00+5.04 (+2.39%) ▲|ORCL126.06-0.10 (-0.08%) ▼|PEP135.46-0.31 (-0.23%) ▼|PFE29.79-0.24 (-0.80%) ▼|PG159.92-1.10 (-0.68%) ▼|PLTR198.84+2.09 (+1.06%) ▲|PM201.87+2.40 (+1.20%) ▲|QCOM179.60+3.69 (+2.10%) ▲|RTX197.48+6.47 (+3.39%) ▲|SBUX102.69+1.89 (+1.88%) ▲|SCHW89.73-0.85 (-0.94%) ▼|SO92.57-0.32 (-0.34%) ▼|SPG212.69+1.06 (+0.50%) ▲|T20.85-0.08 (-0.38%) ▼|TMO684.89+11.07 (+1.64%) ▲|TMUS146.93+0.39 (+0.27%) ▲|TSLA391.62+19.40 (+5.21%) ▲|TXN298.12+13.43 (+4.72%) ▲|UBER66.13-0.57 (-0.85%) ▼|UNH410.70-7.39 (-1.77%) ▼|UNP296.97+4.10 (+1.40%) ▲|UPS100.32-0.74 (-0.73%) ▼|USB59.70+0.12 (+0.20%) ▲|V404.16-3.76 (-0.92%) ▼|VZ43.10-1.56 (-3.49%) ▼|WFC82.65+0.26 (+0.32%) ▲|WMT120.29+0.40 (+0.33%) ▲|XOM184.54+1.33 (+0.73%) ▲|
20.7 C
New York
Tuesday, October 27, 2026

Tag: small cell lung cancer

newsFORsourcecompanycontentinformation1releasesmarket

Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment BiologySEOUL, South Korea, Oct. 24,...

Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

-  At the recommended Phase 3 dose (RP3D) of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% (27/33) and...

Full-Life Technologies Reports Encouraging Preliminary Phase 1 Safety and PSA Decline for FL-020 in mCRPC at ESMO 2026

Data updates from the ongoing Phase 1 dose-escalation study demonstrated promising therapeutic index in patients with mCRPCNo dose-limiting toxicities observed; xerostomia has been predominantly...

OncoC4 Announces NMPA Acceptance of Two IND Applications for Cesalatamig Combination Studies with ADCs and Pan-RAS Inhibitors

— New Studies Expand Cesalatamig into Biomarker-driven Precision Immuno-oncology Strategies— Cesalatamig is Also Being Evaluated in Ongoing Phase 2 Studies in the United States and in...

AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio

New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse...

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

First Phase 1 data for sofetabart mipitecan, Lilly's investigational FRα-targeting ADC, in platinum-sensitive ovarian cancer to be featured in a rapid oral presentationUpdated first-line...

Actinium Pharmaceuticals Announces Inducement Grants to New Employees

NEW YORK, Oct. 16, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies,...

Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development

– Brings more than 20 years of oncology business development and commercial leadership, including senior roles across the radiopharmaceutical sector at Bayer, Clovis Oncology,...

Racura Oncology Cleared to Escalate RC220 to 100 mg/m2 in Phase 1 HARNESS-1 Trial in EGFR-Mutant Non-Small Cell Lung Cancer

The HARNESS-1 Safety Review Committee identified no dose-limiting toxicities or treatment-related safety concerns in either Cohort 1 patient during the safety observation period and...

Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development

Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & Early Translational Lead,...

Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development

Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & Early Translational Lead,...

Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026

–  PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanced bladder cancer –– VYLOY™ (zolbetuximab) research reinforces the role of CLDN18.2...

Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell

— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI.— The Company is...

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors....

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSmall cell lung cancer

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers